Meeting
2019 ASCO Annual Meeting
A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies.
Authors
Oliver Klein
Medical Oncology Unit, Austin Health, Heidelberg, Australia
Oliver Klein , Damien Kee , Ben Markman , Rachael Chang Lee , Michael Michael , Linda R. Mileshkin , Clare L. Scott , Richelle Linklater , Sid Menon , Niall C. Tebbutt , Jodie Palmer , Andreas Behren , Jonathan S. Cebon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT02923934
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2570)
DOI
10.1200/JCO.2019.37.15_suppl.2570
Abstract #
2570
Poster Bd #
214
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers.
First Author: Oliver Klein
Poster
2020 ASCO Virtual Scientific Program
Combination immunotherapy with ipilimumab and nivolumab in patients with rare gynaecological malignancies.
First Author: Oliver Klein
First Author: Sylvie Lorenzen
Poster
2023 ASCO Annual Meeting
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
First Author: Aaron Scott Mansfield